Lunai Bioworks Enters Exclusive Worldwide License And Collaboration Agreement With Tanaist To Add Human Cellular Phenotyping To Its Parkinson's Disease Discovery And Validation Platform
The collaboration is designed to connect patient subtypes identified by BioSymetrics, Lunai's wholly owned subsidiary, using its Augusta AI platform with independent patient cohorts and measurable human cellular
Lunai partnered with Tanaist to study human cells for Parkinson's disease research. This helps them understand different patient types and test treatments more carefully.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.